Lisa Wipperman Heine’s career in Medtech was launched when she answered a want ad in a newspaper – remember those? That path took her to top regulatory and clinical affairs positions at several high-profile Medtechs including Acorn Cardiovascular, ev3, and Covidien. Now, Wipperman Heine sits in the CEO chair of stealthy heart failure start-up PreCardia. We’ll learn a bit about PreCardia and the steps Lisa took to prepare for her new role.
Lisa Wipperman Heine
President & CEO
Lisa Wipperman Heine is currently President & CEO of PreCardia, Inc., an early stage medtech company developing an innovative catheter-based intervention for the treatment of acute decompensated heart failure. Prior to PreCardia, Lisa was most recently Chief Operating Officer at Mitralign, Inc., a venture-backed company focused on development of transcatheter heart valve technologies. Lisa has also served in multiple leadership roles at Covidien, Inc., including Global Vice President of Medical Affairs for Vascular Therapies. During her tenure at Covidien, she helped drive the strategy in support of a $1.7B business and was also responsible for leading the strategy and operations of Clinical Affairs, Healthcare Economics, Policy and Reimbursement and Medical Education functions. Lisa also currently serves as an independent member of the Board of Directors of Surmodics Inc. (NASDAQ: SRDX) and Natus Medical (NASDAQ: BABY).
Meet Our Host
A follower and fan of medtech for nearly two decades, Tom Salemi is the former bureau chief, venture capital, at Elsevier Business Intelligence, where he oversaw coverage of venture investments in medtech.